Modern biotechnologies have yielded processes and products which have commercial significance. Protecting intellectual property for these applications critical for commercial viability of innovator projects has been a challenge. Patent protection for living organisms became possible subsequent to the award of a patent for a modified bacterium not found in nature ( Diamond v. Chakrabarty , 1980), which was created through human ingenuity. Patents for animals were not granted till the late 1980s, as they were not considered subject matter, although in the United States new plant varieties could be protected by plant patents. In 1987, the USPTO announced that it would consider patents for non-naturally occurring, non-human multicellular living organisms, including animals resulting in the patenting of the OncoMouse in 1988. Patenting DNA sequences has been possible as sequences isolated from living organisms are considered compositions of matter and articles of manufacture. However, there is an increasing emphasis on sequences which demonstrate a “substantial, credible, and specific use” only being eligible for patenting.
[1]
R. Cook-Deegan,et al.
Patents in genomics and human genetics.
,
2010,
Annual review of genomics and human genetics.
[2]
Utsa Mukherjee.
A Study of the Basmati Case (India-US Basmati Rice Dispute): The Geographical Indication Perspective
,
2008
.
[3]
E. Gold,et al.
The European Biotech Directive: Past as Prologue
,
2001
.
[4]
G. MorelliGradi.
Patenting biotechnologies: the European Union Directive 98/44/EC of the European parliament and of the council of 6th July 1998 on the legal protection of biotechnological inventions.
,
1999
.
[5]
D. Blake,et al.
Patenting human genes and stem cells.
,
2007,
Recent patents on DNA & gene sequences.